[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-liver-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-liver-fibrosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100375766","phase-2-erlotinib-for-hepatocellular-carcinoma-chemoprevention-100375766",false,"NCT04172779","Erlotinib for Hepatocellular Carcinoma Chemoprevention","Phase II Clinical Trial of Low-dose Erlotinib for Hepatocellular Carcinoma Chemoprevention","ECHO-B","Inclusion Criteria:\n\n* Adults (≥ 18 years-old)\n* Clinically and\u002For histologically diagnosed advanced liver fibrosis or cirrhosis\n* No active hepatic decompensation\n* No prior history of HCC\n* FIB-4 index \\> 3.25\n* PLSec score ≥ 3\n* Adequate hematologic, hepatic, and renal function, Karnofsky performance status score ≥70\n* Both sexes and all racial\u002Fethnic groups will be considered\n\nExclusion Criteria:\n\n* Prior treatment with epidermal growth factor receptor (EGFR) inhibitors\n* Uncontrolled intercurrent, use of CYP3A4 modulators\n* Erlotinib treatment \\\u003C4 weeks or \\\u003C80% of planned regimen at the end of week 4\n* HCC development during the study","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.",[27,28],"Cirrhosis, Liver","Advanced Liver Fibrosis",[30,31],"hepatocellular carcinoma","chemoprevention","NOT_YET_RECRUITING","2026-06-20",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":21},"2026-12",{"date":40,"type":21},"2030-08",{"name":42,"class":43},"University of Texas Southwestern Medical Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100506883","screaning-of-advanced-liver-fibrosis-using-non-invasive-tests-in-general-population-100506883","NCT05880173","SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population","SCREANIT","Inclusion Criteria:\n\n* Age between 18 and 70 years\n* Blood sample taken at a medical testing laboratory selected for the study.\n* Biology without high risk of false positive result for FIB4 (AST and ALT ≤ 300 IU\u002Fl ; Platelets ≥ 50 G\u002Fl and \\\u003C 500 G\u002Fl.)\n* FIB4 \\> 2.67 after automatic calculation in the medical laboratory less than 3 months old\n* Signature of informed consent to participate in the study\n\nExclusion Criteria:\n\n* Ongoing specialized follow-up for a chronic liver disease\n* Difficulty understanding the French language\n* Pregnant women, breastfeeding or parturient women\n* Persons suspended from liberty by judicial or administrative decision\n* Persons under legal protection\n* Persons unable to express their consent\n* Non affiliation to a social security system","75 Years",{"count":54,"type":21},502,[56],"NA","The main objective of the study is to evaluate the pertinence of initiating screening for advanced hepatic fibrosis after a FIB4 result \\> 2.67 automatically calculated in the local laboratory and followed by a specialized hepatic evaluation.",[59,28],"Screening",[59,61,62],"advanced liver fibrosis","non-invasive tests","RECRUITING","2025-12-01",{"date":66,"type":36},"2025-12-08",{"date":68,"type":36},"2023-10-20",{"date":70,"type":21},"2027-03",{"name":72,"class":73},"University Hospital, Angers","OTHER_GOV",6]